Table 1. Demographic and clinical characteristics for all the groups analyzed in our study.
| PTL with PTD Group vs PTL with TD Group | PTD with BPD Group vs PTD with no BPD Group | |||
|---|---|---|---|---|
| PTD Group (n = 13) | TD Group (n = 11) | PTD with BPD Group (n = 10) | PTD with no BPD Group (n = 11) | |
| GA at amniocentesis (wks) | 24 (23–26) | 26 (23–26) | 26 (23–26) | 26 (24–27) |
| GA at delivery (wks) | 27 (26–31) | 39 (38–39) | 26 (26–26) | 27 (26–34) |
| Amniocentesis-to-Delivery interval (days) | 23 (7–49) | 98 (83–114) | 0 (0–16) | 24 (1–53) |
| Males | 7 | 8 | 7 | 7 |
| BW (gr) | 1035 (900–2075) | 3595 (3270–3685) | 786 (635–900) | 1260 (925–2500) |
| Cesarean Section | 4 | 1 | 6 | 4 |
| Maternal Age at amniocentesis (yrs) | 29 (27–31) | 32 (31–36) | 30.5 (24–39) | 30 (29–34) |
| Maternal BMI | 22 (21–24) | 20 (19.9–23.6) | 25.7 (20.2–25.7) | 22 (20–24.38) |
| Smoke during pregnancy | 0 | 1 | 0 | 0 |
| Maternal Ethnicity | 1 African; 1Asian; 11 Caucasian | 1 African; 10 Caucasian | 1 African; 9 Caucasian | 1 Asian; 10 Caucasian |
| Previous miscarriages | 4 | 4 | 4 | 2 |
| Trans-abdominal amniocentesis sampling | 13 | 11 | 4 | 9 |
| Maternal therapy at amniocentesis | 9 Betamethasone; 6 Atosiban; 1 Progesterone; 1 Nifedipine | 7 Betamethasone; 4 Atosiban; 3 Progesterone; 1 Nifedipine | 6 Betamethasone; 3 Atosiban; 1 Progesterone; 2 Nifedipine | 8 Betametasone; 8 Atosiban; 1 Progesterone; 1 Nefedipine |
Data are expressed as median (IQR) or as absolute number of subjects. PTD = preterm delivery; TD = term delivery; PTL = preterm labor; BPD = bronchopulmonary dysplasia; GA = gestational age; BW = birth weight; SGA = small for gestational age; BMI = body mass index.